- Home
- FWONA vs ILMN Comparison
FWONA vs ILMN Comparison
Compare FWONA & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FWONA | ILMN |
|---|---|---|
| Founded | 1950 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.3B | 20.5B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | FWONA | ILMN |
|---|---|---|
| Price | $80.90 | $150.45 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 17 |
| Target Price | $106.00 | ★ $123.00 |
| AVG Volume (30 Days) | 125.5K | ★ 1.7M |
| Earning Date | 02-26-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.84 | ★ 4.46 |
| Revenue | $4,040,000,000.00 | ★ $4,288,000,000.00 |
| Revenue This Year | $24.39 | N/A |
| Revenue Next Year | $9.20 | $2.38 |
| P/E Ratio | $97.13 | ★ $33.69 |
| Revenue Growth | ★ 8.72 | N/A |
| 52 Week Low | $68.00 | $68.70 |
| 52 Week High | $99.52 | $155.53 |
Technical Indicators
Market Signals| Indicator | FWONA | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 34.49 | 61.31 |
| Support Level | $80.93 | $137.00 |
| Resistance Level | $82.91 | $155.53 |
| Average True Range (ATR) | 2.10 | 6.00 |
| MACD | -0.39 | 0.35 |
| Stochastic Oscillator | 11.90 | 74.38 |
Price Performance
Historical ComparisonAbout FWONA Liberty Media Corporation Series A Liberty Formula One
Liberty Media Corp along with its subsidiaries is engaged in the media and entertainment industries in North America and the United Kingdom. The company owns interests in a high-quality portfolio of assets across the media, entertainment and sports industries. The company derives its maximum revenue from United Kingdom.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.